Could Thermo Fisher Scientific Inc. (NYSE:TMO) be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential. William Blair initiated coverage on Tuesday on Thermo Fisher Scientific, citing a strong balance sheet and impressive M&A track record.
Analyst Matt Larew notes that Thermo Fisher has outperformed the S&P 500 over the past decade, delivering a 290% return since 2015, compared to the index's 213%.
